Last reviewed · How we verify
Nystatin oral suspension
Nystatin binds to ergosterol in fungal cell membranes, creating pores that cause leakage and cell death.
Nystatin binds to ergosterol in fungal cell membranes, creating pores that cause leakage and cell death. Used for Oral candidiasis (thrush), Esophageal candidiasis, Intestinal candidiasis.
At a glance
| Generic name | Nystatin oral suspension |
|---|---|
| Also known as | Nystatin Swish and Swallow, Mycostatin |
| Sponsor | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
| Drug class | Polyene macrolide antifungal |
| Target | Ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Nystatin is a polyene macrolide antibiotic that selectively targets ergosterol, a sterol unique to fungal cell membranes. By binding to ergosterol, it disrupts membrane integrity and increases permeability, leading to loss of cellular contents and fungal cell death. It is not absorbed systemically when given orally, making it ideal for topical treatment of oral and gastrointestinal candidiasis.
Approved indications
- Oral candidiasis (thrush)
- Gastrointestinal candidiasis
- Candida infections of the oral cavity and esophagus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Oral irritation
Key clinical trials
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (PHASE1, PHASE2)
- Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients (PHASE3)
- Effects of Nystatin Suspension Oral Application on Oral Microbial Community (PHASE1)
- Curcumin; Rose Bengal; Denture Stomatitis (PHASE3)
- Pharmacokinetics of Sublingual Versus Oral Tacrolimus in Patients Awaiting Kidney Transplantation (PHASE4)
- Photobiomodulation in Oral Lichen Planus (NA)
- Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: